Anomalous levels of Cl- transporters cause a decrease of GABAergic inhibition in human peritumoral epileptic cortex

Luca Conti1, Eleonora Palma, Cristina Roseti

  • 1Pasteur Institute-Cenci Bolognetti Foundation, Department of Physiology and Pharmacology, University of Rome La Sapienza, Rome, Italy.

Epilepsia
|June 4, 2011
PubMed
Abstract

Insights

Altered expression of chloride transporters NKCC1 and KCC2 in brain tumors disrupts GABAergic inhibition, contributing to epilepsy. This suggests targeted therapies for tumor-related seizures.

Area of Science:

  • Neuroscience
  • Oncology
  • Molecular Biology

Background:

  • Epileptogenesis in brain tumors involves reduced GABAergic inhibition.
  • Disrupted chloride homeostasis in the peritumoral microenvironment is a key factor in glioma-related epilepsy.
  • Altered chloride homeostasis may also influence tumor cell migration and metastasis.

Purpose of the Study:

  • To investigate if altered NKCC1 and KCC2 transporter activity in human epileptic peritumoral cortex reduces GABAergic inhibition, contributing to tumor-related epilepsy.
  • To examine the role of chloride ion (Cl(-)) transporters in the development of epilepsy associated with brain tumors.

Main Methods:

  • Injected membranes from epileptic and non-epileptic human cortical tissues into Xenopus oocytes.
  • Recorded GABA-evoked currents using two-microelectrode voltage-clamp.
  • Performed immunoblot analysis and immunohistochemical staining on patient tissues.

Main Results:

  • GABA-evoked currents showed a more depolarized reversal potential in epileptic peritumoral cortex tissues.
  • This shift was reversed by NKCC1 blocker bumetanide or KCC2 unblocker TPEN.
  • Increased expression of NKCC1 and, to a lesser extent, KCC2 transporters was observed in epileptic tissues, with prominent NKCC1 immunoreactivity in neurons.

Conclusions:

  • Altered expression of NKCC1 and KCC2 transporters perturbs chloride homeostasis in epileptic peritumoral human cortex.
  • This perturbation leads to a positive shift in the GABA reversal potential, reducing GABAergic inhibition.
  • These findings highlight the critical role of Cl(-) transporters in tumor-related epilepsy, suggesting potential therapeutic targets.

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...